This resistance could be reversed by the PI3K inhibitor BKM120, suggesting that anti-HER2 therapies together with PI3K inhibitors may be a beneficial combination for the clinical treatment of HER2+/PIK3CA-mutant breast cancers [43]. This evidence concerns the gene PIK3CD and breast carcinoma.